Biogroup announced that it had presented the preclinical results of NK cell
therapy at the '2022 International Conference: The Korean Society for Molecular
and Cellular Biology' (KSMCB) on the 30th.
Korean Society for Molecular and Cellular Biology, a world-renowned academic
conference on cell biology, is held at the Jeju International Convention Center
from September 28 to 30 this year.
the human immune system, NK cells are the most powerful immune cells that
remove abnormal cells from the body. Its ability to remove cancer cells to
prevent the occurrence, proliferation, metastasis, and recurrence of cancer has
been confirmed, and worldwide research is being actively conducted as a cancer
treatment without side effects using natural immunity.
official of NKCL Bio Group Inc. said, “The NK cell therapy was tested for
breast cancer, lung cancer, liver cancer, and kidney cancer. Based on the
preclinical results showing a higher anticancer effect compared to the
cisplatin control group, it is confirmed that the NK cell therapy of NKCL has
an excellent ability to kill cancer cells.” said.
Cisplatin: A chemical anticancer drug widely used for cancer treatment, which
has good initial effects but has large side effects and causes cancer cells to
NK cell immunotherapy, which is the core business of NKCL Bio Group, is a cell therapeutics
that has an excellent effect on killing cancer cells. It is possible to
commercialize a drug for the purpose of treating cancer or rare diseases at an
early stage by obtaining conditional approval after phase 2 clinical trials.
Based on the successful preclinical results of NK
cell therapy, NKCL Bio Group has completed the CRO contract for clinical 1/2a.